20 Slash 20 Inc., the innovator behind The Eye Drink, will be featured in coverage of the upcoming Disruptive Growth & Life Sciences Conference, hosted by Moody Capital Solutions Inc. This event, scheduled for 2026, brings together emerging companies and investors, with a focus on disruptive growth sectors. The company's inclusion in the conference underscores the growing market for preventive health products, particularly those targeting the widespread problem of digital eye strain.
The Eye Drink is described as the world's first clinically inspired, ready-to-drink functional beverage specifically formulated to minimize ocular issues in today's screen-heavy world. With an estimated average of 7+ hours per day spent on digital devices, the product aims to reduce screen-induced dry eyes and potential macular damage. The formulation leverages science-backed nutrients based on the AREDS 2 studies and includes vegan-friendly triglyceride-formed Omega-3 to support visual performance and improve ocular comfort.
20 Slash 20 Inc. is modernizing preventive eyecare by transforming clinical science into a convenient daily habit. The company distributes through direct-to-consumer channels, professional medical affiliates, and natural product retail stores. This multi-channel approach allows it to reach health-conscious consumers and professionals alike.
The conference, organized by Moody Capital Solutions, an independent investment bank with over 40 years of experience in capital raising, M&A, and advisory services, is recognized as a market leader in rights offerings. The event provides a platform for companies like 20 Slash 20 to connect with potential investors and partners.
IBN, a multifaceted financial news and publishing company, is providing comprehensive coverage of the conference. Through its custom-built portal, IBN offers summaries on each participating company, enabling investors to evaluate opportunities efficiently. IBN also utilizes social media and syndicated articles to maximize visibility of the event, extending its reach to millions of investors daily.
The participation of 20 Slash 20 in this conference represents a significant opportunity for the company to showcase its innovative product to a wider audience. As digital device usage continues to rise, the demand for solutions to mitigate ocular discomfort is likely to grow, positioning The Eye Drink as a timely entry in the functional beverage market. The conference coverage by IBN will further amplify the company's message and could attract strategic partnerships or investment.
For more information about The Eye Drink, visit theeyedrink.com. To register for the conference, visit Moody Capital's conference page. IBN's coverage of the event is available at IBN's conference coverage. For more on IBN, visit IBN.Ai. Disclaimers apply to all content provided by IBN, as detailed on IBN's disclaimer page.
